Replies to post #4134 on Synaptogenix Inc (SNPX)

[runncoach]

Interesting even the folks that tweet they think we won't have positive data, readily admit this is a rocket launcher if data is good. It's a pioneering MOA and what has failed between phase 2 and 3 for other MOAs doesn't apply to our thesis. That's what some skeptics fail to see. I admit it may not work, but if it helps a significant number in this trial, the alzheimer's world will put its focus on us. Good luck gang. IR still confirming April so we'll know in less than 48 hours.

[NotRichYet2]

That's a GIVEN but they are if you noticed they are part of a tag team take down group.

[Wildginger]

For the sake of many people I hope they are wrong.

[InTheTrenches]

$30 Billion spent over the last 20 years on Alzheimer's research, drug development and clinical trials...with no drug that can actually halt or reverse the disease.

Tells me that 95%+ of neurology researchers don't understand the causes of AD.

I'm convinced that Dr. Alkon, with 45 years of research, understands the underlying causes. And, after re-listening the February 13 BIOCeo Neurotrope presentation, I believe he is certain that he has identified a drug that can halt or reverse this insidious disease.

Let's hope that almost all of the patients, drug and placebo, were able to complete the 17 week course of drug infusion and psychiatric tests.

[Maple tree]

Not worry about them and AF was wrong about CPXX. He seems pretty positive on axon and don't know why. Good phase2b data will crush axon too. Luckily, adding shares yesterday and wait for the news